Stockscreener 앱 받기
1.80
0.82%
-0.02
전일 마감가:
$1.82
열려 있는:
$1.84
하루 거래량:
3.26M
Relative Volume:
1.12
시가총액:
$190.06M
수익:
-
순이익/손실:
$-37.34M
주가수익비율:
-1.3235
EPS:
-1.36
순현금흐름:
$-36.91M
1주 성능:
-6.96%
1개월 성능:
-3.48%
6개월 성능:
+3.74%
1년 성능:
+51.68%
1일 변동 폭
$1.73
$1.85
1주일 범위
$1.73
$2.12
52주 변동 폭
$0.772
$2.48
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
명칭
Sellas Life Sciences Group Inc
전화
(646) 200-5278
주소
7 TIMES SQUARE, NEW YORK, NY
SLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
1.805 | 268.34M | 0 | -37.34M | -36.91M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.56 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.11 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.09 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.14 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.19 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-07-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-11-01 | 개시 | Oppenheimer | Outperform |
| 2018-04-02 | 개시 | H.C. Wainwright | Buy |
| 2018-03-19 | 업그레이드 | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc 주식(SLS)의 최신 뉴스
SELLAS to present SLS009 data for relapsed leukemia at ASH meeting - Investing.com
SELLAS Life Sciences (NASDAQ: SLS) to present SLS009 with azacitidine and venetoclax in AML-MR at ASH 2025 - Stock Titan
SELLAS Life Sciences Group Inc. stock prediction for this weekLong Setup & Weekly High Return Stock Opportunities - newser.com
SELLAS Life Sciences Group Inc. stock trend forecastJuly 2025 PreEarnings & Long-Term Investment Growth Plans - newser.com
Analyzing SELLAS Life Sciences Group Inc. with risk reward ratio chartsJuly 2025 Momentum & Safe Investment Capital Preservation Plans - newser.com
Does SELLAS Life Sciences Group Inc. fit your quant trading modelQuarterly Trade Review & Safe Capital Investment Plans - newser.com
Should you wait for a breakout in SELLAS Life Sciences Group Inc.2025 Dividend Review & Daily Chart Pattern Signal Reports - newser.com
Can SELLAS Life Sciences Group Inc. stock sustain revenue growthJuly 2025 Reactions & Long-Term Growth Plans - newser.com
SELLAS Life Sciences Group Inc. stock outlook for YEAR2025 Stock Rankings & Community Consensus Stock Picks - newser.com
Does SELLAS Life Sciences Group Inc. show high probability of reboundJuly 2025 Sector Moves & Verified Stock Trade Ideas - newser.com
Understanding SELLAS Life Sciences Group Inc.’s price movementProduct Launch & Safe Entry Trade Signal Reports - newser.com
Is SELLAS Life Sciences Group Inc. reversing from oversold territory2025 Trading Recap & AI Driven Price Predictions - newser.com
Using economic indicators to assess SELLAS Life Sciences Group Inc. potentialJuly 2025 EndofMonth & Real-Time Market Sentiment Alerts - newser.com
Is SELLAS Life Sciences Group Inc. showing signs of accumulation2025 Price Momentum & Reliable Volume Spike Trade Alerts - newser.com
Can SELLAS Life Sciences Group Inc. (RXK3) stock hold up in economic slowdownTrade Risk Assessment & High Win Rate Trade Alerts - newser.com
What technical models suggest about SELLAS Life Sciences Group Inc.’s comeback2025 Volume Leaders & Advanced Swing Trade Entry Alerts - newser.com
Is SELLAS Life Sciences Group Inc. stock attractive for retirement portfoliosMarket Risk Analysis & Growth Focused Entry Reports - newser.com
Will SELLAS Life Sciences Group Inc. (RXK3) stock test record highs in 2025July 2025 Fed Impact & Consistent Profit Focused Trading Strategies - newser.com
How SELLAS Life Sciences Group Inc. stock valuations compare to rivalsMarket Performance Summary & AI Forecasted Entry and Exit Points - newser.com
Why Is SELLAS Life Sciences Stock Falling Today? - MSN
How institutional ownership impacts SELLAS Life Sciences Group Inc. stockInflation Watch & Breakout Confirmation Alerts - newser.com
Sellas Life Sciences Group Inc (SLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.19%
1.82%
자본화:
|
볼륨(24시간):